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2Abstract 2-Thioxo-3,9,10,11-tetrahydro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]
pyrimidin-4-one (4) was prepared by the reaction of 2-dimethylaminomethylenebenzosuberone
(1) with 6-amino-1-phenyl-2-thioxo-2,3-dihydro-pyrimidin-4-one (2). 2-Hydrazino-9,10,11-tri-
hydro-1-phenyl-benzo-[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]pyrimidin-4-one (5) was prepared
in good yield by reaction of 4 with hydrazine hydrate under reﬂux. Reaction of compound 5 with
different aldehydes in acetic acid gave the corresponding hydrazono derivatives 6. Cyclization of
the latter compounds with bromine in acetic acid afforded a series of novel pentaheterocyclic
compounds namely, 7,8,9-trihydro-4-phenyl-benzo[600,700]cyclohepta[100,200:40,50]pyrido[20,30-
d][1,2,4]triazolo[4,3-a]pyrimidin-14-ones (7a–g). Some of the newly synthesized compounds
showed potent antitumor activity against HEPG-2 ‘‘liver’’ cancer cell line and MCF-7 ‘‘breast’’
cancer cell line.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The search for anticancer drugs led to the discovery of several
hydrazones having anticancer activity. A report on aryl-
idenehydrazinopyrimidines deals with the activity of these5676608.
m (T.A. Farghaly).
Saud University.
g by Elsevier
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riazolo[4,3-a]pyrimidin-5-ones.compounds as anticancer and immunomodulating agents
(Dlugosz and Machon, 1995). Easmon et al. (2001) reported
on the cytotoxic effect of N-heteroaryl hydrazones that are
particularly selective against colon carcinoma and that exhibit
a novel mechanism of action. Hwu et al. have reported that
photolytic cleavage of the nitrogen–nitrogen single bond in
benzaldehyde phenylhydrazones produced aminyl (R2N) and
iminyl (R2C‚N) radicals. This photochemical property was
utilized in the development of hydrazones as photoinduced
DNA cleaving agents (Hwu et al., 2004). Many derivatives
of fused benzocycloheptanone are potent antitumoral agents
(Afonso et al., 2001; Benoit et al., 2000) against L1210 murine
leukemia and HT29 cell lines. Also, the inhibition of theing Saud University.
. Synthesis and antitumor activity of benzo[600,700]cyclohep-
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2 M.M. Edrees, T.A. Farghalyfarnesyl protein transferase, a novel approach to antitumor
therapy is based on compounds such as substituted cyclohep-
tapyridines (Ganguly et al., 2001). In continuation of our re-
search work concerned with the synthesis of bioactive
heterocyclic compounds (Abdel Hafez et al., 2010; Riyadh
et al., 2010a,b; Farghaly and Abdalla, 2009; Farghaly et al.,
2012; Edrees et al., 2010), we report herein the synthesis of a
new series of 2-[(substitutedmethylene)hydrazono]-9,10,11-
trihydro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]
pyrimidin-4-one and benzo[600,700]cyclohepta[100,200:40,50]pyr-
ido[20,30-d][1,2,4]triazolo[4,3-a]pyrimidin-14-ones to evaluate
their anti-tumor properties against two human tumor cell lines
(MCF7 ‘‘breast’’ and HEPG2 ‘‘liver’’ cancers).2. Experimental
2.1. Chemistry
Melting points were determined on a Gallenkamp apparatus
and are uncorrected. IR spectra were recorded in a Pye-Uni-
cam SP300 instrument in potassium bromide disks. 1H NMR
and 13C NMR spectra were recorded in a Varian Mercury
VXR-300 spectrometer (300 MHz for 1H and 75 MHz for
13C) in DMSO-d6 and the chemical shifts were related to that
of the solvent. Mass spectra were recorded in a GCMS-QP
1000 EX Shimadzu Spectrometer, the ionizing voltage was
70 eV. Elemental analyses were carried out at the Microanalyt-
ical Laboratory of Cairo University, Giza, Egypt. The anti-tu-
mor activities were evaluated at the Regional Center for
Mycology and Biotechnology at Al-Azhar University, Cairo,
Egypt.
2.1.1. Synthesis of 2-thioxo-3,9,10,11-tetrahydro-1-phenyl-benzo
[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]pyrimidin-4-one (4)
A mixture of enaminone 1 (Farghaly et al., 2010) (2.15 g,
10 mmol) and 6-amino-1-phenyl-2-thioxo-3H-pyrimidin-4-
one (2) (2.19 g, 10 mmol) in glacial acetic acid (30 mL) was
heated under reﬂux for 5 h. After cooling, the reaction mixture
was poured into ice/HCl mixture and the solid product was
collected and recrystallized from dioxane as white crystals,
yield (3.15 g, 85%) mp > 300 C. 1H NMR (DMSO-d6)
d ppm: 2.16–2.54 (m, 6H, 3CH2), 7.09–7.52 (m, 9H, ArH),
8.35 (s, 1H, pyridine-H), 12.89 (s, 1H, NH, D2O exchange-
able). IR m cm1: 3107 (NH), 1704 (C‚O), 1291 (C‚S)
cm1. Ms m/z (%) 373 (M++2, 4), 372 (M++1, 19), 371
(M+, 67), 370 (100), 312 (3), 180 (6), 156 (1), 142 (2), 77
(23). Anal. Calcd. for C22H17N3OS (371.45) C, 71.14; H,
4.61; N, 11.31. Found: C, 71.03; H, 4.36; N, 11.51%.
2.1.2. Synthesis of 2-hydrazino-9,10,11-trihydro-1-phenyl-benzo
[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]pyrimidin-4-one (5)
To thione 4 (1.86 g, 5 mmol) in ethanol (20 mL) was added
hydrazine hydrate (10 mL, 80%). The reaction mixture was re-
ﬂuxed till all H2S (30 h) ceased to evolve, and then cooled. The
solid that precipitated was ﬁltered off and crystallized from
ethanol to give compound 5 (1.44 g, 78%) as yellow solid.
m.p. 260–262 C. 1H NMR (DMSO-d6) d ppm: 2.16–2.50 (m,
6H, 3CH2), 3.37 (br, 2H, NH2, D2O exchangeable),
6.92–8.01 (m, 9H, ArH), 8.18 (s, 1H, pyridine-H), 10.81 (s,Please cite this article in press as: Edrees, M.M., Farghaly, T.A
ta[100,200:40,50]pyrido[20,30-d] [1,2,4]triazolo[4,3-a]pyrimidin-5-ones.
10.1016/j.arabjc.2013.06.0021H, NH, D2O exchangeable).
13C NMR (DMSO-d6) d ppm:
28.71, 30.63, 32.56, 118.68, 120.67, 121.00, 123.96, 126.34,
128.58, 128.88, 129.78, 135.39, 137.15, 138.04, 139.36, 140.66,
151.54, 158.02, 160.32, 166.68. IR m cm1: 3350, 3290, 3188
(NH, NH2), 1644 (C‚O) cm
1. Ms m/z (%) 369 (M+, 12),
353 (28), 339 (15), 312 (14), 207 (7), 166 (13), 153 (11), 127
(16), 113 (10), 91 (8), 90 (6), 89 (13), 77 (100). Anal. Calcd.
for C22H19N5O (369.42) C, 71.53; H, 5.18; N, 18.96. Found:
C, 71.25; H, 5.25; N, 18.74%.2.1.3. Preparation of hydrazones 6a–g
A mixture of hydrazine 5 (0.92 g, 2.5 mmol) and the appropri-
ate aldehyde 6 (2.5 mmol) in acetic acid (20 mL) and few drops
of conc. hydrochloric acid (1 mL) was heated under reﬂux for
3 h. The reaction mixture was then cooled and diluted with
water. The so-formed solid product was then collected by ﬁl-
tration, dried and crystallized from the proper solvent to af-
ford the corresponding hydrazones 6a–g.2.1.3.1. 2-[(Phenylmethylene)hydrazono]-9,10,11-trihydro-1-
phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]pyrimi-
din-4-one (6a). Pale yellow crystals (0.71 g, 75%) m.p. 268–
270 C (ethanol) 1H NMR (DMSO-d6) d ppm: 1.91–2.35 (m,
6H, 3CH2), 7.31–7.41 and 7.95–7.97 (m, 14H, ArH), 7.68 (s,
1H, N‚CH), 8.19 (s, 1H, pyridine-H), 11.60 (br s, 1H, NH,
D2O exchangeable). IR m cm
1: 3173 (NH), 1680 (C‚O)
cm1. Ms m/z (%) 458 (M++1, 10), 457 (M+, 40), 192 (40),
165 (12), 103 (34), 92 (85), 77 (100). Anal. Calcd. for
C29H23N5O (457.53) C, 76.13; H, 5.07; N, 15.31. Found: C,
76.01; H, 4.99; N, 15.19%.2.1.3.2. 2-[(4-Methylphenylmethylene)hydrazono]-9,10,11-tri-
hydro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-
d]pyrimidin-4-one (6b). Yellow crystals (0.94 g, 80%) m.p.
218–220 C (ethanol) 1H NMR (DMSO-d6) d ppm: 2.17–2.59
(m, 6H, 3CH2), 2.45 (s, 3H, CH3), 7.17–8.04 (m, 13H, ArH),
8.25 (s, 1H, N‚CH), 8.65 (s, 1H, pyridine-H), 10.97 (s, 1H,
NH, D2O exchangeable).
13C NMR(DMSO-d6) d ppm:
20.83, 28.58, 30.30, 32.12, 108.85, 120.53, 126.20, 126.60,
127.69, 128.32, 128.46, 128.54, 128.85, 129.03, 129.14, 129.31,
129.69, 132.09, 136.50, 137.05, 138.10, 139.35, 139.44, 150.13,
158.69, 162.58. IR m cm1: 3342 (NH), 1696 (C‚O) cm1.
Ms m/z (%) 472 (M+1, 20), 471 (M+, 25), 380 (33), 221 (8),
193 (24), 144 (18), 120 (21), 77 (49). Anal. Calcd. for
C30H25N5O (471.55) C, 76.41; H, 5.34; N, 14.85. Found: C,
76.25; H, 5.20; N, 14.70%.2.1.3.3. 2-[(4-Methoxyphenylmethylene)hydrazono]-9,10,11-
trihydro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-
d]pyrimidin-4-one (6c). Yellow solid (0.99 g, 82%) m.p. 300–
302 C (ethanol) 1H NMR (DMSO-d6) d ppm: 2.15–2.80 (m,
6H, 3CH2), 3.28 (s, 3H, OCH3), 6.93–8.03 (m, 13H, ArH),
8.04 (s, 1H, N‚CH), 8.25 (s, 1H, pyridine-H), 10.93 (s, 1H,
NH, D2O exchangeable). IR m cm
1: 3205 (NH), 1687
(C‚O) cm1. Ms m/z (%) 488 (M++1, 21), 487 (M+, 73),
380 (54), 271 (6), 207 (15), 122 (6), 120 (12), 107 (30), 91
(49), 77 (100). Anal. Calcd. for C30H25N5O2 (487.55)
C, 73.90; H, 5.17; N, 14.36. Found: C, 73.68; H, 5.01; N,
14.22%.. Synthesis and antitumor activity of benzo[600,700]cyclohep-
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hydro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-
d]pyrimidin-4-one (6d). Yellow crystals (0.92 g, 75%) m.p.
240–242 C (ethanol) 1H NMR (DMSO-d6) d ppm: 2.18–2.50
(m, 6H, 3CH2), 7.18–8.04 (m, 13H, ArH), 8.08 (s, 1H,
N‚CH), 8.27 (s, 1H, pyridine-H), 11.25 (s, 1H, NH, D2O
exchangeable). IR m cm1: 3434 (NH), 1709 (C‚O) cm1.
Ms m/z (%) 493 (M++2, 20), 492 (M++1, 28), 491 (M+,
41), 380 (100), 353 (29), 339 (3), 312 (4), 205 (8), 165 (19),
153 (18), 124 (14), 111 (34), 91 (7), 90 (13), 89 (85), 77 (82).
Anal. Calcd. for C29H22ClN5O (491.97) C, 70.80; H, 4.51; N,
14.24. Found: C, 70.66; H, 4.28; N, 14.51%.
2.1.3.5. 2-[(4-Nitrophenylmethylene)hydrazono]-9,10,11-trihy-
dro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-
d]pyrimidin-4-one (6e). Dark orange solid (0.90 g, 72%) m.p.
250–252 C (ethanol) 1H NMR (DMSO-d6) d ppm: 2.21–2.60
(m, 6H, 3CH2), 7.27–8.32 (m, 14H, ArH, NH D2O exchange-
able), 8.35 (s, 1H, N‚CH), 8.69 (s, 1H, pyridine-H). IR
m cm1: 3421(NH), 1716 (C‚O) cm1. Ms m/z (%) 503
(M+, 2), 392 (24), 367 (8), 353 (5), 339 (2), 295 (100), 225
(2), 193(7), 131 (7), 111 (15), 91 (36), 89 (4), 77(4). Anal. Calcd.
for C29H22N6O3 (502.52) C, 69.31; H, 4.41; N, 16.72. Found:
C, 69.20; H, 4.21; N, 16.65%.
2.1.3.6. 2-[(4-Dimethylaminophenylmethylene)hydrazono]-
9,10,11-trihydro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyr-
ido[2,3-d]pyrimidin-4-one (6f). Yellow solid (65%) m.p.
>300 C (ethanol/dioxane) 1H NMR (DMSO-d6) d ppm:
2.20–2.62 (m, 6H, 3CH2), 3.55 (s, 6H, 2CH3), 6.87–7.69 (m,
14H, ArH, NH D2O exchangeable), 7.89 (s, 1H, N‚CH),
8.60 (s, 1H, pyridine-H). IR m cm1: 3315 (NH), 1690
(C‚O) cm1. Ms m/z (%) 500 (M+, 1), 499 (1), 336 (14),
281 (35), 254 (27), 251 (12), 207 (11), 191 (20), 76 (100). Anal.
Calcd. for C31H28N6O (500.59) C, 74.38; H, 5.64; N, 16.79.
Found: C, 74.27; H, 5.39; N, 16.52%.
2.1.3.7. 2-[(2-Furfurylmethylene)hydrazono]-9,10,11-trihydro-
1-phenylbenzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]pyrimi-
din-4-one (6g). Yellow crystals (0.76 g, 68%) m.p. 270–272 C
(ethanol) 1H NMR (DMSO-d6) d ppm: 1.91–2.63 (m, 6H,
3CH2), 6.66–7.64 (m, 13H, ArH, NH, D2O exchangeable),
7.89 (s, 1H, N‚CH), 8.67 (s, 1H, pyridine-H). IR m cm1:
3422 (NH), 1718 (C‚O) cm1. Ms m/z (%) 447 (M+, 2),
380 (3), 368 (6), 353 (3), 339 (3), 221 (3), 195 (11), 142 (5),
76 (14). Anal. Calcd. for C27H21N5O2 (447.49) C, 72.47; H,
4.73; N, 15.65. Found: C, 72.32; H, 4.60; N, 15.42%.
2.1.4. Synthesis of 7,8,9-trihydro-4-phenyl-benzo[600,700]cyclo-
hepta[100,200:40,50]pyrido[20,30-d][1,2,4]triazolo[4,3-a]pyrimidin-
14-ones (7a–g)
Bromine (0.052 g, 1 mmol) in acetic acid (5 mL) was added
dropwise to a stirred solution of the appropriate hydrazone
6a–g (1 mmol of each) in acetic acid (10 mL). The reaction
mixture was then poured into ice cold water, and the solid that
precipitated was ﬁltered off, washed with sodium bicarbonate
solution and then with water, dried and crystallized from the
appropriate solvent to give the respective compounds 7a–g.
2.1.4.1. 1,4-Diphenyl-7,8,9-trihydro-benzo[600,700]cyclohepta[100,
200:40,50]pyrido[20,30-d][1,2,4]triazolo[4,3-a]pyrimidin-14-onePlease cite this article in press as: Edrees, M.M., Farghaly, T.A
ta[100,200:40,50]pyrido[20,30-d] [1,2,4]triazolo[4,3-a]pyrimidin-5-ones.
10.1016/j.arabjc.2013.06.002(7a). Yellow solid (0.28 g, 62%) m.p. 246–248 C (ethanol).
1H NMR (DMSO-d6) d ppm: 2.22–2.62 (m, 6H, 3CH2),
7.34–8.25 (m, 14H, ArH), 8.69 (s, 1H, pyridine-H). IR m cm1:
1717 (C‚O) cm1. Ms m/z (%) 457 (M++2, 5), 456 (M++1,
22), 455 (M+, 54), 454 (16), 295 (49), 192 (29), 178 (10), 165
(19), 115 (14), 103 (29), 77 (100). Anal. Calcd. for
C29H21N5O (455.51) C, 76.47; H, 4.65; N, 15.37. Found: C,
76.62; H, 4.41; N, 15.06%.
2.1.4.2. 1-(4-Methylphenyl)-7,8,9-trihydro-4-phenyl-benzo
[600,700]cyclohepta[100,200:40,50]pyrido[20,30-d][1,2,4]triazolo
[4,3-a]pyrimidin-14-one (7b). Pale yellow (0.32 g, 68%) m.p.
258–260 C (ethanol) 1H NMR (DMSO-d6) d ppm: 2.34–
2.61(m, 6H, 3CH2), 2.63 (s, 3H, CH3), 7.31–7.99 (m, 13H,
ArH), 8.48 (s, 1H, pyridine-H). IR m cm1: 1695 (C‚O)
cm1. Ms m/z (%) 471 (M++2, 11), 469 (M+, 35), 296 (20),
295 (37), 192 (32), 165 (30), 118 (20), 115 (33), 91 (44), 89
(22), 77 (100). Anal. Calcd. for C30H23N5O (469.54) C, 76.74;
H, 4.94; N, 14.92. Found: C, 76.52; H, 4.63; N, 14.66%.
2.1.4.3. 1-(4-Methoxyphenyl)-7,8,9-trihydro-4-phenyl-benzo
[600,700]cyclohepta[100,200:40,50]pyrido[20,30-d][1,2,4]triazol-
o[4,3-a]pyrimidin-14-one (7c). Orange crystals (0.33 g, 69%)
m.p. 230–232 C (ethanol) 1H NMR (DMSO-d6) d ppm:
2.19–2.55 (m, 6H, 3CH2), 4.58 (s, 3H, OCH3), 7.31–7.99 (m,
13H, ArH), 8.55 (s, 1H, pyridine-H). IR m cm1: 1705
(C‚O) cm1. Ms m/z (%) 486 (M++1, 21), 485 (M+, 18),
297 (18), 296 (36), 191 (29), 165 (32), 164 (32), 103 (18),
89 (21), 77 (100). Anal. Calcd. for C30H23N5O2 (485.54)
C, 74.21; H, 4.77; N, 14.42. Found: C, 74.10; H, 4.60;
N, 14.20%.
2.1.4.4. 1-(4-Chlorophenyl)-7,8,9-trihydro-4-phenyl-benzo-
[600,700]cyclohepta[100,200:40,50]pyrido[20,30-d][1,2,4]triazolo-
[4,3-a]pyrimidin-14-one (7d). Yellow solid (0.30 g, 62%) m.p.
290–292 C (ethanol) 1H NMR (DMSO-d6) d ppm: 2.06–2.62
(m, 6H, 3CH2), 7.16–8.05 (m, 13H, ArH), 8.62 (s, 1H, pyri-
dine-H). IR m cm1 1698 (C‚O) cm1. Ms m/z (%) 491
(M++2, 6), 490 (M++1, 18), 489 (M+, 55), 297 (48), 233
(15), 111 (83), 89 (67), 77 (100). Anal. Calcd. for C29H20ClN5O
(489.95) C, 71.09; H, 4.11; N, 14.29. Found: C, 71.24; H, 4.28;
N, 14.08%.
2.1.4.5. 1-(4-Nitrophenyl)-7,8,9-trihydro-4-phenyl-benzo[600,700]
cyclohepta[100,200:40,50]pyrido[2’,3’-d][1,2,4]triazolo[4,3-a]
pyrimidin-14-one (7e).Orange solid (64%)m.p.>300 C (diox-
ane) 1H NMR (DMSO-d6) d ppm: 1.90–2.41 (m, 6H, 3CH2),
7.03–7.80 (m, 13H, ArH), 8.35 (s, 1H, pyridine-H). IR m cm1
1690 (C‚O) cm1. Ms m/z (%) 501 (M++1, 10), 500 (M+,
25), 89 (60), 77 (100). Anal. Calcd. for C29H20N6O3 (500.51)
C, 69.59;H, 4.03;N, 16.79. Found:C, 69.31;H, 4.10;N, 16.63%.
2.1.4.6. 1-(4-Dimethylaminophenyl)-7,8,9-trihydro-4-phenyl-
benzo[600,700]cyclohepta[100,200:40,50]pyrido[20,30-d][1,2,4]triaz-
olo[4,3-a]pyrimidin-14-one (7f). Orange solid (62%) m.p.
>300 C (dioxane) 1H NMR (DMSO-d6) d ppm: 2.01–2.48
(m, 6H, 3CH2), 3.62 (s, 6H, 2CH3), 6.97–8.02 (m, 13H,
ArH), 8.58 (s, 1H, pyridine-H). IR m: 1685 (C‚O) cm1. Ms
m/z (%) 499 (M++1, 2), 498 (M+, 24), 124 (45), 114 (85),
89 (58), 77 (100). Anal. Calcd. for C31H26N6O (498.58)
C,74.68; H, 5.26; N, 16.86. Found: C, 74.42; H, 5.09; N,
16.80%.. Synthesis and antitumor activity of benzo[600,700]cyclohep-
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4 M.M. Edrees, T.A. Farghaly2.1.4.7. 1-(2-Furfuryl)-7,8,9-trihydro-4-phenyl-benzo[600,700]
cyclohepta[100,200:40,50]pyrido[20,30-d][1,2,4]triazolo[4,3-a]
pyrimidin-14-one (7g). Yellow solid (0.30 g, 60%) m.p. 286–
288 C (ethanol) 1H NMR (DMSO-d6) d ppm: 1.91–2.40 (m,
6H, 3CH2), 7.35–7.89 (m, 12H, ArH), 8.47 (s, 1H, pyridine-
H). IR m cm1 1678 (C‚O) cm1. Ms m/z (%) 445 (M+,
100), 367 (15), 114 (18), 89 (25), 77 (95). Anal. Calcd. for
C27H19N5O2 (445.47): C, 72.80; H, 4.30; N, 15.72. Found: C,
72.65; H, 4.22; N, 15.57%.
2.2. Pharmacology
2.2.1. Anticancer activity
The anticancer activity of the synthesized compounds 5, 6 and
7 was determined against the human breast cell line (MCF-7)
and the liver carcinoma cell line (HEPG-2), using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay and doxorubicin was used as a reference drug.Please cite this article in press as: Edrees, M.M., Farghaly, T.A
ta[100,200:40,50]pyrido[20,30-d] [1,2,4]triazolo[4,3-a]pyrimidin-5-ones.
10.1016/j.arabjc.2013.06.002Data generated were used to plot a dose response curve of
which the concentration of test compounds required to kill
50% of cell population (IC50) was determined. Cytotoxic activ-
ity was expressed as the mean IC50 of three independent exper-
iments (Table 1). The method applied is similar to that
reported by Vijayan et al. (2004) using Crystal violet stain
(1%). Cells were seeded in 96-well plate at a cell concentration
1 · 104 cells per well in 100 ll of growth medium. Fresh med-
ium containing different concentrations of the test sample was
added after 24 h of seeding. Serial twofold dilutions of the
tested chemical compound were added to conﬂuent cell mono-
layers, ﬂat-bottomed microtiter plates using a multichannel
pipette. The microtiter plates were incubated at 37 C in a
humidiﬁed incubator with 5% CO2 for 48 h. Three wells were
used for each concentration of the test sample. Control cells
were incubated without test sample with DMSO. After incuba-
tion of the cells for 24 h at 37 C, various concentrations of
sample (50, 25, 12.5, 6.25, 3.125, and 1.56 lg) were added,. Synthesis and antitumor activity of benzo[600,700]cyclohep-
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Table 1 IC50 of the selected tested compounds against
HEPG-2 ‘‘liver’’ cancer cell line and MCF-7 ‘‘breast’’ cancer
cell line.
Compound No. IC50 (lM) IC50 (lM)
HEPG-2 cell line MCF-7 cell line
5 16.38 1.98
6a 22.35 21.56
6b 6.58 12.34
6c 0.18 0.26
6d 10.24 21.01
6f 0.49 0.88
6g 45.21 35.24
7a >50 >50
7b 3.65 0.85
7c 1.05 5.14
7e 3.94 >50
7f 2.68 14.07
7g >50 >50
Doxorubicin 0.469 0.426
Synthesis and antitumor activity of benzo[600,700]cyclohepta[100,200:40,50]pyrido[20,30-d]and the incubation was continued for 48 h and the viable cells’
yield was determined by a colorimetric method (Carmichael
et al., 1987). After the end of the incubation period, media
were aspirated and the crystal violet solution was added to
each well for at least 30 min. The stain was removed and the
plates were rinsed using tap water until all excess stain is re-
moved. Acetic acid (30%) was then added to all wells and
mixed thoroughly, and then the absorbance of the plates was
measured after gently shaking on Microplate reader, using a
test wavelength of 490 nm. All results were corrected for back-
ground absorbance detected in wells without added stain.
Treated samples were compared with the cell control in the ab-
sence of the tested compounds. All experiments were carried
out in triplicate. The cell cytotoxic effect of each tested com-
pound was calculated (Table 1).
3. Results and discussion
3.1. Chemistry
Reaction of 2-dimethylaminomethylenebenzosuberone (1)
with 6-amino-1-phenyl-2-thioxopyrimidin-4-one (2) in glacial
acetic acid under reﬂux gave novel tetra-heterocyclic ring
system, namely, 2-thioxo-3,9,10,11-tetrahydro-1-phenyl-benzo-
[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]pyrimidin-4-one (4)
(Scheme 1). Mass, IR spectra and elemental analysis data of
the isolated product were consistent with each of the isomeric
structures 3 and 4 (Scheme 1), while, 1H NMR spectra revealed
singlet signal at d 8.35 ppm assigned for pyridine-2H proton
not pyridine-4H proton (Quiroga et al., 2002; Ahmed and
Farghaly, 2009) which was consistent with the isomeric struc-
ture 4 not the isomer structure 3.
Our target 2-hydrazino-9,10,11-trihydro-1-phenyl-ben-
zo[60,70]cyclo-hepta[10,20:4,5]pyrido[2,3-d]pyrimidin-4-one (5)
was prepared by treating compound 4 with hydrazine hydrate
in absolute ethanol under reﬂux till all H2S ceased to evolve
about 30 h (Scheme 1). The structure of compound 5 was elu-
cidated on the basis of spectral data and microanalysis. For
example, the IR spectrum revealed absorption bands at 3350,
3290, 3188, 1644 cm1 assignable to NH2, NH, and C‚O,
respectively. The 1H NMR spectrum showed characteristic
broad signal at d= 3.37 ppm assigned for the protons of the
NH2 group. In addition, the
13C NMR revealed 19 carbon at
d 28.71, 30.63, 32.56, 118.68, 120.67, 121.00, 123.96, 126.34,
128.58, 128.88, 129.78, 135.39, 137.15, 139.36, 140.66, 151.54,
158.02, 160.32, 166.68 ppm.
Condensation of 2-hydrazino-9,10,11-trihydro-1-phenyl-
benzo[60,70]cyclohepta[10,20:4,5]pyrido[2,3-d]pyrimidin-4-one
(5) with different aldehydes in acetic acid containing few drops
of conc. hydrochloric acid gave the corresponding hydrazone
derivatives 6a–g (Scheme 1). The mass spectra of the isolated
products 6a–g showed the molecular ion peaks at the expected
m/z values. Their IR spectra showed the disappearance of the
NH2 group, and revealed in each case a carbonyl band in the
region 1717–1695 cm1. Also, 1H NMR spectra showed, in
each case, the presence of the azomethine at d= 7.68–
8.35 ppm.
Treatment of each of the hydrazones 6 with bromine in acetic
acid in the presence of sodium acetate with stirring gave, in each
case, a single product as evidenced by TLC analysis. Elemental
analyses and mass spectra revealed that each of such isolatedPlease cite this article in press as: Edrees, M.M., Farghaly, T.A
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This ﬁndingwas conﬁrmed by 1HNMR spectra which indicated
the absence of the –N‚CH– and hydrazone –NH–N‚C pro-
tons. On the basis of this ﬁnding, the isolated products were as-
signed the structure of 7,8,9-trihydro-4-phenyl-benzo
[600,700]cyclohepta[100,200:40,50]pyrido[20,30-d][1,2,4]triazolo[4,3-a]
pyrimidin-14-ones (7a–g) (Scheme 1).3.2. Pharmacology
3.2.1. Anticancer activity
The in vitro anti-tumor activity of the tested compounds 5, 6a–
d,f,g and 7a–c,e–g was evaluated at the Regional Center for
Mycology and Biotechnology at Al-Azhar University, Cairo,
Egypt, against HEPG-2 ‘‘liver’’ cancer cell line and MCF-7
‘‘breast’’ cancer cell line. Doxorubicin was used as a reference
and showed IC50 = 0.469 and 0.426 lg/mL against (HEPG-2)
and (MCF-7) cell lines, respectively. Some of the tested com-
pounds showed effects against both cancer cell lines as shown
in Table 1.
3-Hydrazino-2,7,8,9-tetrahydro-1-phenyl-benzo[60,70]cyclo-
hepta[10,20:4,5]pyrido[2,3-d] pyrimidin-4-one (5) has activity
against MCF-7 ‘‘breast’’ cancer cell line with IC50 = 1.98 lg/mL.
Regarding the activities of the hydrazone derivatives 6a–d,f,g
in Table 1, compounds 6c showed reactivity on the two tumor-
al cell lines more than the reference drug. Also, compound 6f
revealed activity near to the reference doxorubicin against
the two cell lines used. While the other derivatives showed
moderate to low activity.
For compounds 7a–c,e–g derivatives 7c has activity against
HEPG-2 ‘‘liver’’ cancer cell line with IC50 = 1.05 lg/mL. In
addition, compound 7b showed activity against MCF-7
‘‘breast’’ cancer cell line (IC50 = 0.85 lg/mL) near to the refer-
ence drug. From these data we can conclude that the most
reactive compounds are the hydrazone derivatives 6c and 6f
which carry electron donating groups (OCH3 and N(CH3)2,
respectively at the phenyl methylenehydrazono group at posi-
tion 3 of compound 6.. Synthesis and antitumor activity of benzo[600,700]cyclohep-
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6 M.M. Edrees, T.A. Farghaly4. Conclusion
In summary, we report herein the synthesis of a new series of
7,8,9-trihydro-4-phenyl-benzo[600,700]cyclohepta[100,200:40,50]pyr-
ido[20,30-d][1,2,4]triazolo[4,3-a]pyrimidin-14-ones (7a–g) from
oxidative cyclization of 2-[(substitutedmethylene)hydrazono]-
9,10,11-trihydro-1-phenyl-benzo[60,70]cyclohepta[10,20:4,5]pyr-
ido[2,3-d]pyrimidin-4-one (6a–g). Compound 6c exhibited high
anti-tumor activity against HEPG-2 ‘‘liver’’ cancer cell line
and MCF-7 ‘‘breast’’ cancer cell line which is more potent than
the reference standard doxorubicin. The other synthesized
compounds revealed good to moderate anti-tumor properties
against HEPG-2 ‘‘liver’’ cancer cell line and MCF-7 ‘‘breast’’
cancer cell line.References
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